Research & Development

AbCellera, Autolus partner on antibody discovery project

AbCellera, a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies, has collaborated with clinical stage biopharmaceutical company Autolus Therapeutics on antibody discovery project.

HOOKIPA, DarwinHealth to collaborate on immunotherapies development

HOOKIPA Pharma has signed a research collaboration and license agreement with DarwinHealth to develop immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.

BeiGene acquires rights to Zymeworks’ ZW25 and ZW49 bispecific candidates in Asia-Pacific

Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.

Roche’s Genentech agrees to buy Jecure Therapeutics

Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.

Cyclica, Bayer partner to advance drug discovery programs

Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.

Vineti, Tessa partner to advance cancer immunotherapies

Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.

Evotec, Immuneering partner on AI-driven approach to ligand identification

Evotec has entered into a research collaboration with Immuneering on artificial intelligence (AI) driven ligand identification for rare hereditary metabolic diseases.

LEO Pharma, PellePharm form $760m rare skin disease collaboration

LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).

Boehringer, Epizyme announce $300m oncology therapy program

Boehringer Ingelheim has entered into a new global collaboration with Epizyme to develop novel epigenetic oncology therapies.